Association between Naturally Acquired Antibodies to Erythrocyte-Binding Antigens of Plasmodium falciparum and Protection from Malaria and High-Density Parasitemia
Details
Publication Year 2010-10-15,Volume 51,Issue #8,Page E50-E60
Journal Title
CLINICAL INFECTIOUS DISEASES
Publication Type
Journal Article
Abstract
Background. Antibodies targeting blood stage antigens are important in protection against malaria, but the principle targets remain unclear. Erythrocyte-binding antigens (EBAs) are important erythrocyte invasion ligands used by merozoites and may be targets of protective immunity, but there are limited data examining their potential importance. Methods. We examined antibodies among 206 Papua New Guinean children who were treated with antimalarials at enrolment and observed prospectively for 6 months for reinfection and malaria. Immunoglobulin (Ig) G, IgG subclasses, and IgM to different regions of EBA175, EBA140, and EBA181 expressed as recombinant proteins were assessed in comparison with several other merozoite antigens. Results. High levels of IgG to each of the EBAs were strongly associated with protection from symptomatic malaria and high density parasitemia, but not with risk of reinfection per se. The predominant IgG subclasses were either IgG1 or IgG3, depending on the antigen. The predominance of IgG1 versus IgG3 reflected structural features of specific regions of the proteins. IgG3 was most strongly associated with protection, even for those antigens that had an IgG1 predominant response. Conclusions. The EBAs appear important targets of acquired protective immunity. These findings support their further development as vaccine candidates.
Publisher
OXFORD UNIV PRESS INC
Keywords
INVASION PATHWAYS; REGION-II; INHIBITORY ANTIBODIES; RECEPTOR SPECIFICITY; TARGETED DISRUPTION; MEROZOITE ANTIGENS; CLINICAL MALARIA; EBA-175; LIGAND; RESPONSES
Publisher's Version
https://doi.org/10.1086/656413
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2010-10-15 12:00:00
An error has occurred. This application may no longer respond until reloaded. Reload 🗙